UNSPSC 51263103: Adimolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C25H29N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6CJY5K2ST, chemically known as (rs)-2,3-dihydro-1-(3-(2-hydroxy-3-(naphthyloxy)propylamino)-3-methylbutyl)-1h-2-benzimidazolon but generally known as adimolol, which bears US NIH Compound Identifier 71227. Adimolol most often comes in forms base, hydrochloride, and hydrate.

UNSPSC 51263103 Adimolol, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The single recent opportunity—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—concerns emergency-response pharmaceuticals and harm-reduction equipment, not adimolol (a beta-blocker medication used to treat hypertension and heart disease). The mismatch suggests either a tagging error in the source data or that this code sees minimal legitimate activity in state and local procurement.

Seminole County's July 2026 IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under a two-year initial term with one-year renewal option. The procurement required electronic bid submission, E-Verify compliance, drug-free workplace certification, and standard commercial general liability and workers compensation insurance, with potential FEMA funding triggering Clean Air Act and Federal Water Pollution Control Act compliance. Without additional recent opportunities clearly aligned to adimolol procurement, the code shows no actionable activity for business development purposes under its nominal scope.